Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy
Joint Authors
Subhi, Yousif
Sørensen, Torben Lykke
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-06-04
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Purpose.
To investigate neovascular age-related macular degeneration (AMD) in patients aged ≥90 years from several perspectives for a comprehensive overview: prevalence, presenting characteristics, treatment adherence, reasons for discontinuation, and efficacy of antivascular endothelial growth factor (VEGF) treatment comparing Ranibizumab and Aflibercept.
Methods.
In this retrospective chart review, we determined the prevalence and presenting characteristics by reviewing all data for patients referred to our department with treatment-naïve neovascular AMD.
By looking at historical cohorts, we determined adherence to treatment, reasons for discontinuation, and treatment outcomes after loading dose, 12 months, and 24 months.
Results.
Patients aged ≥90 years constituted 7% of the patients.
Treatment was discontinued in 51%, primarily because of death and treatment burden.
Mean change in best-corrected visual acuity was 3.2, 1.5, and −2.2 ETDRS letters at 4, 12, and 24 months, respectively.
Aflibercept was superior to Ranibizumab in visual and anatomic outcomes.
After two years of treatment, patients losing ≥15 ETDRS letters made up 19% in the Aflibercept group and 26% in the Ranibizumab group.
Conclusions.
We propose that the very old patients with neovascular AMD may constitute a distinctive group warranting special attention and possibilities for individualized therapy.
Possible differences between anti-VEGF agents need further investigations.
American Psychological Association (APA)
Subhi, Yousif& Sørensen, Torben Lykke. 2017. Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy. Journal of Ophthalmology،Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1185295
Modern Language Association (MLA)
Subhi, Yousif& Sørensen, Torben Lykke. Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy. Journal of Ophthalmology No. 2017 (2017), pp.1-9.
https://search.emarefa.net/detail/BIM-1185295
American Medical Association (AMA)
Subhi, Yousif& Sørensen, Torben Lykke. Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy. Journal of Ophthalmology. 2017. Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1185295
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1185295